58
Participants
Start Date
May 25, 2019
Primary Completion Date
January 30, 2023
Study Completion Date
January 30, 2023
Abraxane
In patients with relapsed. metastatic breast cancer, ORIN1001 will be administered in combination with Abraxane administered by intravenous infusion.
ORIN1001
ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer
NYU Langone Health, New York
Northwell Health, New Hyde Park
Northwell Heath Cancer Institute, New Hyde Park
Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI)), Buffalo
Thomas Jefferson University Hospital, Philadelphia
University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center, Miami
Sarah Cannon Research Institute, Nashville
Gabrail Cancer Center, Canton
St Lukes Cancer Institute, Kansas City
Cancer Center of Kansas, Wichita
Baylor College of Medicine Medical Center, Houston
University of Colorado Anschutz Medical Campus, Denver
University of Colorado Lone Tree Medical Center, Lone Tree
Highlands Ranch Hospital, Highlands Ranch
Banner MD Anderson Cancer Center, Gilbert
University of Arizona Cancer Center, Tucson
University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC) - Oncology Center - Westwood, Westwood, Los Angeles
UCLA Health Burbank Specialty Care, Burbank
UCLA Health Laguna Hills Cancer Care, Laguna Hills
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange
Lead Sponsor
Orinove, Inc.
INDUSTRY